Preliminary favorable outcome for medically and surgically managed extensively drug-resistant tuberculosis, France, 2009-2014

Emerging Infectious Diseases

Volumn 22, Issue 3, 2016, Pages 518-521

  Henry, Benoît ^a,b,e   Revest, Matthieu ^c   Dournon, Nathalie ^a   Epelboin, Loïc ^a,b   Mellon, Guillaume ^a   Bellaud, Guillaume ^a   Mordant, Pierre ^d   Le Dû, Damien ^e   Véziris, Nicolas ^a,b,f,g   Bernard, Christine ^a,f   Morel, Sébastien ^a,b   Jauréguiberry, Stéphane ^a,g   Michelet, Christian ^c,h   Bricaire, François ^a,b   Tattevin, Pierre ^b,c,h   Caumes, Éric ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f Ctr Natl de Reference des Mycobacteries et de la Resistance des Mycobacteries Aux Antituberculeux   (France)

^g Assistance publique Hôpitaux de Paris   (France)

^h UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BEDAQUILINE; CAPREOMYCIN; CARBAPENEM; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; IMIPENEM; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG SENSITIVITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; FRANCE; HUMAN; LOBECTOMY; LUNG RESECTION; MALE; OUTCOME ASSESSMENT; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HISTORY; MULTIMODALITY CANCER THERAPY; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; COMBINED MODALITY THERAPY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; FOLLOW-UP STUDIES; FRANCE; HISTORY, 21ST CENTURY; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME;

EID: 84958749963     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2203.151130     Document Type: Article

References (15)

1. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2010;51:6-14. http://dx.doi.org/10.1086/653115.
2. Bernard C, Brossier F, Sougakoff W, Veziris N, Frechet-Jachym M, Metivier N, et al. A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union. Euro Surveill. 2013;18:20555.
3. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. 2011 update [cited 2015 Apr 4]. http://www.ncbi.nlm.nih.gov/books/NBK148644/.
4. Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, Cegielski JP. Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA. 2008;300:2153-60. http://dx.doi.org/10.1001/jama.300.18.2153.
5. Pietersen E, Ignatius E, Streicher EM, Mastrapa B, Padanilam X, Pooran A, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet. 2014;383:1230-9. http://dx.doi.org/10.1016/S0140-6736(13)62675-6.
6. Abubakar I, Moore J, Drobniewski F, Kruijshaar M, Brown T, Yates M, et al. Extensively drug-resistant tuberculosis in the UK: 1995 to 2007. Thorax. 2009;64:512-5. http://dx.doi.org/10.1136/ thx.2008.108712.
7. Banerjee R, Allen J, Westenhouse J, Oh P, Elms W, Desmond E, et al. Extensively drug-resistant tuberculosis in California, 1993-2006. Clin Infect Dis. 2008;47:450-7. http://dx.doi.org/10.1086/590009.
8. Bendayan D, Hendler A, Polansky V, Weinberger M. Outcome of hospitalized MDR-TB patients: Israel 2000-2005. Eur J Clin Microbiol Infect Dis. 2011;30:375-9. http://dx.doi.org/10.1007/s10096-010-1096-7.
9. Minion J, Gallant V, Wolfe J, Jamieson F, Long R. Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics. PLoS ONE. 2013; 8:e53466. http://dx.doi.org/10.1371/journal.pone.0053466.
10. Jeon DS, Kim DH, Kang HS, Hwang SH, Min JH, Kim JH, et al. Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2009;13:594-600.
11. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371:723-32. http://dx.doi.org/10.1056/NEJMoa1313865.
12. Shean K, Streicher E, Pieterson E, Symons G, van Zyl Smit R, Theron G, et al. Drug-associated adverse events and their relation-ship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS ONE. 2013; 8:e63057. http://dx.doi.org/10.1371/journal.pone.0063057.
13. Ndjeka N, Conradie F, Schnippel K, Hughes J, Bantubani N, Ferreira H, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis. 2015;19:979-85. http://dx.doi.org/10.5588/ijtld.14.0944.
14. Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS ONE. 2013;8:e54587. http://dx.doi.org/10.1371/journal.pone.0054587.
15. Yong Kim J, Shakow A, Mate K, Vanderwarker C, Gupta R, Farmer P. Limited good and limited vision: multidrug-resistant tuberculosis and global health policy. Soc Sci Med. 2005;61:847-59. http://dx.doi.org/10.1016/j.socscimed.2004.08.046.